16:29 , Apr 2, 2019 |  BC Extra  |  Financial News

Ocular oncology play Aura raises $40M D round

Medicxi led a $40 million series D round for Aura as the ocular oncology company prepares its lead choroidal melanoma therapy for Phase III testing in 1H20. The funding will give Aura Biosciences Inc. (Cambridge,...
22:40 , Mar 18, 2019 |  BC Extra  |  Financial News

OrbiMed, Arix lead Imara's $63M B round

Imara will use its $63 million series B round to prepare lead compound IMR-687 for a Phase III program in adults with sickle cell disease, and to position the oral phosphodiesterase-9 (PDE-9) inhibitor for pediatric...
00:10 , Feb 20, 2019 |  BC Extra  |  Company News

Management tracks: Allergan, Arix, Quest, SurModics

Allergan plc (NYSE:AGN) appointed Robert Hugin to its board. He stepped down as CEO of Celgene Corp. (NASDAQ: CELG) in 2016, and retired as Celgene's executive chairman last year. Mark Alles is Celgene's current chairman...
23:30 , Feb 13, 2019 |  BC Week In Review  |  Financial News

Harpoon slips after pricing $75.6M IPO

Harpoon Therapeutics Inc. (NASDAQ:HARP) raised $75.6 million in an IPO that priced at the midpoint of its proposed range. Harpoon sold 5.4 million shares at $14, within the $13-$15 range. The price gave Harpoon a...
04:00 , Feb 8, 2019 |  BC Extra  |  Financial News

Harpoon slips after pricing $75.6M IPO

Harpoon Therapeutics Inc. (NASDAQ:HARP) shares lost $0.50 to $13.50 in their first day of trading Friday after the company raised $75.6 million in an IPO that priced at the midpoint of its proposed range. Harpoon...
21:35 , Jan 11, 2019 |  BioCentury  |  Emerging Company Profile

Artios: Probing DNA Damage

With programs in-licensed from Cancer Research UK and Masaryk University, Artios Pharma Ltd. thinks it has next-generation DNA damage response programs that could improve upon PARP inhibitors -- and the funds to take them to...
22:03 , Jan 4, 2019 |  BC Week In Review  |  Financial News

On heels of series C, Harpoon files for IPO

Less than two months after raising a $70 million series C round, Harpoon Therapeutics Inc. (South San Francisco, Calif.) filed on Dec. 27 to raise $86.3 million in an IPO on NASDAQ. Harpoon is developing...
23:06 , Dec 27, 2018 |  BC Extra  |  Financial News

On heels of series C, Harpoon files for IPO

Less than two months after raising a $70 million series C round, Harpoon Therapeutics Inc. (South San Francisco, Calif.) filed Thursday to raise $86.3 million in an IPO on NASDAQ. Harpoon is developing tri-specific T...
15:57 , Nov 16, 2018 |  BC Week In Review  |  Financial News

Harpoon raises $70M ahead of additional Phase I starts for TriTACs

Harpoon Therapeutics Inc. (South San Francisco, Calif.) raised $70 million on Nov. 11 in a series C round led by new investor OrbiMed Advisors, as the immunotherapy company gears up to bring two more of...
21:02 , Nov 12, 2018 |  BC Extra  |  Financial News

Harpoon raises $70M ahead of additional Phase I starts for TriTACs

Harpoon Therapeutics Inc. (South San Francisco, Calif.) raised $70 million in a series C round led by new investor OrbiMed Advisors, as the immunotherapy company gears up to bring two more of its T cell...